C.?The Association for the Accreditation of Human Research Protection Programs Inc. today announced that it has awarded accreditation to four additional organizations, including one more in Korea.
The Association for the Accreditation of Human Research Protection Programs Inc
. today announced that it has awarded accreditation to four additional organizations, including one more in Korea. The newly accredited organizations are:
The accreditations are the latest example of AAHRPP’s continued growth throughout the research enterprise. They also reflect AAHRPP’s steady progress in achieving the goal of one standard worldwide for protecting research participants and advancing high-quality research.
“These accreditations underscore that AAHRPP’s standards apply equally well to organizations across the research spectrum,” said Marjorie A. Speers, Ph.D., AAHRPP president and CEO. “AAHRPP accreditation is widely regarded as the mark of a quality human research protection program worldwide.”
AAHRPP accreditation is available to U.S. and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. To date, AAHRPP has accredited organizations in 46 states, Canada, China, India, Korea, Mexico, Singapore and Taiwan.
Since its founding in 2001, AAHRPP has been instrumental in persuading research organizations to focus on quality improvement and routinely assess their performance. As a result, today’s AAHRPP-accredited HRPPs can point to measurable improvements in advancing research, protecting participants and building public trust.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.